Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
Editas Medicine’s presentations at ARVO will include preclinical data demonstrating:
- Gene edited USH2A exon 13 deletion restored USH2 protein complex expression and rescued deficits in photoreceptor morphology in human retinal organoids; and
- Clinically relevant levels of editing using a dual AAV CRISPR-Cas9 system as a therapeutic strategy for the treatment of
RP4 .
“Editas Medicine is making significant advancements in our efforts to treat ocular diseases, and we look forward to sharing recent progress and preclinical data on our USH2A and
The complete list of
Oral Presentation:
CRISPR Gene Editing Rescues Deficits in Human USH2A Mutant Retinal Organoids
Date/Time:
Session: Gene Therapy in Ocular Diseases
Poster Presentation:
Advances Towards a Dual AAV CRISPR-Cas9-based ‘Knockout and Replace’ Strategy to Treat Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa
Date/Time:
Session: Gene Editing and Ocular Therapies
About
As a leading genome editing company,
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
Contacts: MediaCristi Barnett (617) 401-0113 cristi.barnett@editasmed.com InvestorsRon Moldaver (617) 401-9052 ir@editasmed.com
Source: Editas Medicine, Inc.